BIOHEART-B (02185) Reports Interim Results with Attributable Loss of RMB 27.213 Million, Up 5.35% YoY

Stock News

Aug 26

BIOHEART-B (02185) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 20.862 million. The company recorded a loss attributable to owners of the parent company of RMB 27.213 million, representing a year-on-year increase of 5.35%. Basic loss per share stood at RMB 0.11.

According to the announcement, the company's revenue for the six-month period ended June 30, 2025, was generated from the commercialization of RDN products. For the six months ended June 30, 2025, the company recognized revenue of RMB 20.9 million (compared to nil for the six months ended June 30, 2024), comprising RMB 20.5 million from product sales and RMB 0.4 million from partnerships.

The company's research and development expenses decreased, primarily attributed to a reduction of RMB 2.3 million in depreciation and amortization expenses, as the majority of machinery and equipment were utilized for production activities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1126628968"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126628968\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126628968?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126628968","market":"hk","top_or_hot":-1,"title":"BIOHEART-B (02185) Reports Interim Results with Attributable Loss of RMB 27.213 Million, Up 5.35% YoY","media":"Stock News","content":"<p>BIOHEART-B (02185) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 20.862 million. The company recorded a loss attributable to owners of the parent company of RMB 27.213 million, representing a year-on-year increase of 5.35%. Basic loss per share stood at RMB 0.11.</p>\n<p>According to the announcement, the company's revenue for the six-month period ended June 30, 2025, was generated from the commercialization of RDN products. For the six months ended June 30, 2025, the company recognized revenue of RMB 20.9 million (compared to nil for the six months ended June 30, 2024), comprising RMB 20.5 million from product sales and RMB 0.4 million from partnerships.</p>\n<p>The company's research and development expenses decreased, primarily attributed to a reduction of RMB 2.3 million in depreciation and amortization expenses, as the majority of machinery and equipment were utilized for production activities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOHEART-B (02185) Reports Interim Results with Attributable Loss of RMB 27.213 Million, Up 5.35% YoY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOHEART-B (02185) Reports Interim Results with Attributable Loss of RMB 27.213 Million, Up 5.35% YoY\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-26 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOHEART-B (02185) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 20.862 million. The company recorded a loss attributable to owners of the parent company of RMB 27.213 million, representing a year-on-year increase of 5.35%. Basic loss per share stood at RMB 0.11.</p>\n<p>According to the announcement, the company's revenue for the six-month period ended June 30, 2025, was generated from the commercialization of RDN products. For the six months ended June 30, 2025, the company recognized revenue of RMB 20.9 million (compared to nil for the six months ended June 30, 2024), comprising RMB 20.5 million from product sales and RMB 0.4 million from partnerships.</p>\n<p>The company's research and development expenses decreased, primarily attributed to a reduction of RMB 2.3 million in depreciation and amortization expenses, as the majority of machinery and equipment were utilized for production activities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"医疗保健设备","start_time":0,"source_url":"","article_id":"1126628968","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126628968","pubTimestamp":1756217660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BIOHEART-B (02185) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 20.862 million. The company recorded a loss attributable to owners of the parent...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1100":"医疗保健设备","02185":"百心安-B"},"translate_title":"生物心脏-B(02185)公布中期业绩应占亏损2721.3万元同比增5.35%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02185":1},"content_text":"BIOHEART-B (02185) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 20.862 million. The company recorded a loss attributable to owners of the parent company of RMB 27.213 million, representing a year-on-year increase of 5.35%. Basic loss per share stood at RMB 0.11.\nAccording to the announcement, the company's revenue for the six-month period ended June 30, 2025, was generated from the commercialization of RDN products. For the six months ended June 30, 2025, the company recognized revenue of RMB 20.9 million (compared to nil for the six months ended June 30, 2024), comprising RMB 20.5 million from product sales and RMB 0.4 million from partnerships.\nThe company's research and development expenses decreased, primarily attributed to a reduction of RMB 2.3 million in depreciation and amortization expenses, as the majority of machinery and equipment were utilized for production activities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}